Tirzepatide

Dual-incretin support for appetite, weight, and metabolic care

Status

Available at launch

Mechanism

Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. It combines the appetite and gastric-emptying effects seen with GLP-1 therapy with additional incretin activity that can improve insulin sensitivity and glycemic control. In practice, it is used for structured titration and long-term metabolic care under clinician oversight.

Indications

→Chronic weight-management support in eligible adults

→Appetite control and caloric-intake reduction

→Metabolic care with obesity or weight-related comorbid risk

→Maintenance plans that require slower dose escalation and monitoring

Regulatory status

Branded tirzepatide products are FDA-approved. Compounded tirzepatide is not FDA-approved and should only be used when a patient's medical needs cannot be met by an available FDA-approved product and applicable compounding rules are met. Northline uses clinician review, titration oversight, and patient-specific medical necessity standards.

References

01FDA. ZEPBOUND (tirzepatide) prescribing information.

02Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.